If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. China’s semaglutide market is heading toward $61B by 2032, unleashing a biosimilar frenzy. Over 25 drugmakers have filed 90+ applications, eight are nearing approval, and a pending patent ruling could trigger price wars that reshape diabetes and obesity care. The FDA and medical experts caution it’s safest to get FDA-approved name-brand drugs through your regular doctor and in-person pharmacy. But some people may feel uncomfortable talking to their doctors because of stigma about weight. Semaglutide is a medication primarily used to manage type 2 diabetes and promote weight loss in adults by regulating blood sugar levels and appetite.
- Currently, over 11 firms, including Huadong Medicine and Livzon New North River, are advancing through clinical trials for semaglutide biosimilars.
- By inhibiting glucagon release, peptides further aid blood sugar control.Slowing gastric emptying and decreasing stomach motility can also change how the gastrointestinal system works when it binds to GLP-1 receptors.
- If these effects are not managed by a healthcare provider, they can become severe or life-threatening.
- While the Denmark-based company expects the drug’s weight-loss counterpart Wegovy to be approved in China later this year, competitors are springing up to get in on the GLP-1 cash cow.
- As a semaglutide manufacturer, Xi’an Sonwu supplies high-purity powder of premium quality at a competitive price.
Under Xi’an Sonwu, researchers can continuously develop high-quality new products.2. Xi’an Sonwu has strict requirements on personnel allocation from production and testing to sales. To ensure that each product is escorted, rigorous data support and after-sales service are provided. CardiovascularAccording to clinical research, it may lower the risk of significant adverse cardiovascular events in people at high risk for cardiovascular disease. The safety and efficacy of it in the cardiovascular system are being studied in the PIONEER 6 research. Nearly 3,000 persons with type 2 diabetes participated in the experiment, discovering that men using it will have a lower risk of cardiovascular events and all-cause death than men taking semaglutide tablets vs injection a placebo.
Give your business an edge with our leading industry insights.
The companies are licensed to make slightly different versions of FDA-approved drugs in response to shortages or a patient’s special needs. Patients pay about $100 to $450 a month, compared with list prices of roughly $1,000 to $1,400 for Lilly and Novo Nordisk products. When administering Ozempic, always be sure to follow the guidance of a doctor or healthcare professional and check the packaging instructions for further safety advice. Calibrate’s The Metabolic Reset weight loss program has a monthly cost of $199 with a 3-month commitment. With this program, you will have access to the company’s medical and support teams at all times, a 30-minute appointment with a doctor to review lab results, and one-to-one coaching every 2 weeks. Zuo Ya-Jun, general manager of weight loss drugmaker Shanghai Benemae Pharmaceutical, said a product being competitive would depend on distinguishing features such as efficacy, durability of the treatment and a company’s sales abilities.
C187H291N45O59 Semaglutide ( Ozempic ) Peptides 5mg White Lyophilized Powder
The CDE’s “under review” catalog lists over 90 pending applications for semaglutide injections, categorized as biologics (Class 3.3) or chemical drugs (Class 2.2), spanning July 2021 to August 2025 from at least 25 domestic companies. Eight companies have reached the marketing application stage, with over 10 others in Phase II/III trials. Below is a summary of filings, organized by earliest submission date per company. Among the frontrunners of the would-be Chinese semaglutide sellers is Hangzhou Jiuyuan Gene Engineering, whose version of semaglutide is said to have “similar clinical efficacy and safety” to Ozempic.
Best for weight tracking
As Novo Nordisk’s patent approaches expiration in 2026, the market for semaglutide biosimilars is rapidly changing. Currently, at least 11 Chinese companies are advancing through clinical trials, paving the way for the introduction of Wegovy and its biosimilars. This expansion will improve treatment options for metabolic syndrome, making effective weight management more accessible to patients. Such advancements have the potential to transform our strategies for addressing obesity and its related health challenges.
All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. Biotech Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Biotech Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. The industry endured just such a catastrophe in 2012, when the New England Compounding Center released a contaminated injectable steroid that killed at least 64 people and harmed hundreds more. More than half of China’s 1.4 billion population are overweight or obese, according to a 2020 report from the country’s National Health Commission.
In China, you can get your hands on Ozempic easily if you know where to look
Supplies of both Wegovy and Zepbound remain constrained, but the companies have been increasing production. Even more pressing for Novo is the China patent office’s 2022 ruling that the patent is invalid for reasons related to experimental data availability, which the company has challenged. Xi’an Sonwu has advanced testing equipment and professional testing personnel, all of which show that Xi’an Sonwu aims to provide accurate and effective data and good service. However, Novo has mounted a legal effort to extend its patent in the country.
However, “the sheer size of China’s healthcare market” — the world’s second-largest — means that companies can recoup their research costs, one pharma marketing executive told Insider. Besides generic drugs, Chinese companies investing in GLP-1 pipeline R&D also bring incremental markets. For example, Huadong Medicine’s GLP-1 product liraglutide covered over 1,000 large hospitals and more than 30,000 pharmacies by the end of the first quarter of 2024. Additionally, in the highly anticipated GLP-1 dual- and triple-target market, fast-moving companies like Innovent’s mazdutide planned to submit a listing application for weight loss indications early this year. Hengrui Medicine and BrightGene Bio-Medical Technology are also in the late stages of clinical trials.
China’s Creating Cheapo Versions of Ozempic That Could Majorly Shake Up the Market
It is important to note that semaglutide should never be used to treat type 1 diabetes. This is a condition in which the body cannot produce insulin and, therefore, cannot regulate sugar in the blood. In this case, if semaglutide is used instead of insulin, it will not work for patients who need insulin. The buying frenzy for semaglutide, an injectable drug, has surged over the past months, as online users flood social media platforms with glowing reviews of the “elixir” weight loss product, domestic outlet Guancha reported Tuesday.
K Health offers a membership option for $49 for the first month and then $147 every 3 months. You will get 24/7 access to urgent care, flexible appointments, unlimited text-based visits, and more. However, if you have insurance, Calibrate has a team that can help you navigate your plans and determine whether medications and lab tests are covered. Additionally, Calibrate provides tools to help improve sleep, exercise, relationship with food, and emotional health. Novo joins a growing list of Big Pharma players that in recent weeks have spoken out against the steps taken by President Donald Trump in a purported effort to lower drug costs in the U.S.